Altamira Therapeutics Ltd (CYTO)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF”No...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Altamira Therapeutics Provides Update on Nasdaq Listing

Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”...

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m...

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form EFFECT - Notice of Effectiveness

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million...

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]